AVNR Profile
Avanir Pharmaceuticals, Inc. (AVNR) was a biopharmaceutical company based in the United States that focused on developing and commercializing treatments for central nervous system disorders. The company was founded in 1988 and was headquartered in Aliso Viejo, California.
In 2015, Avanir Pharmaceuticals was acquired by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company. Under the terms of the acquisition, Otsuka paid $17.00 per share in cash for all outstanding shares of Avanir, which represented a total transaction value of approximately $3.5 billion.
At the time of the acquisition, Avanir Pharmaceuticals had a number of products on the market, including Nuedexta, which was approved by the U.S. Food and Drug Administration for the treatment of pseudobulbar affect (PBA). Additionally, the company had a number of other products in development, including treatments for multiple sclerosis and agitation associated with Alzheimer's disease.
It's important to note that since cutoff date of September 2021, there may have been updates or developments regarding Avanir Pharmaceuticals and its products or acquisition by Otsuka Pharmaceutical Co.
|
